The medtech company Vibrosense Dynamics reports small changes in its revenue and results in the first quarter. Revenue fell to SEK 0.3 million (0.8).Operating profit/loss was SEK -1 million (-1.2). Profit/loss after tax was SEK -1 million (-1.2). Earnings per share amounted to SEK -0.03 (-0.05)."We continue to build on the foundations we laid during 2025. We see continued strong interest from clinics and researchers in Europe in our priority segments, diabetes, oncology and occupational health. Development in Asia is proceeding according to plan except in China, where we are still waiting for our distributor UMCare to get started," says CEO Toni Speidel. He continues."The work to broaden our international presence continues according to plan and we now have concrete opportunities in several new markets. The company has, among other things, established very promising contacts in Hong Kong, Singapore and Malaysia. A distribution agreement has recently been signed in Turkey with the distributor Alpmed, which has initiated work on the regulatory registration of our instrument in Turkey."The Vibrosense Dynamics CEO further writes that the company has good cost control and is entering 2026 with a strong financial position that makes it possible to invest in international expansion. Under "Outlook" he writes the following. "Vibrosense enters the remainder of 2026 with a positive feeling after many new promising signals, and we see a clear trend toward increased business opportunities. With a strong and growing international pipeline, we look forward to establishing new distributor partnerships before the summer. In combination with ongoing clinical collaborations and an established presence in, among other places, the United Kingdom, Spain, Ireland and China, the company has a broad platform for continued growth."Vibrosense Dynamics, SEK mQ1-2025/2026Q1-2024/2025ChangeNet sales0.30.8-62.5%Operating profit/loss-1-1.2Net profit/loss-1-1.2Earnings per share, SEK-0.03-0.05